Cystic Fibrosis Related Diabetes Published In The Journal Of Cystic Fibrosis Articles & Analysis
44 news found
A Centers for Disease Control and Prevention (CDC) report published on October 3, 2024, linked Burkholderia multivorans infections to ice machines in multiple healthcare facilities in the western United States. This post summarizes key findings, implications, and recommended practices for healthcare providers to ensure patient ...
Vitalograph has joined forces with MedM Inc. to further enhance patient respiratory monitoring experience with digital health capabilities. The MedM health monitoring app is paired with Vitalograph’s Asthma-1 BT and Lung Monitor BT Smart devices. The app works as a digital asthma or lung function diary, helping users to better understand and manage their condition. Patient diaries like ...
Protein Metrics Inc., a leading provider of biopharmaceutical and proteomics analysis software, announced today a new partnership to advance glycoproteomics and biotherapeutics tools and research Macquarie University’s Analytical Glycoimmunology Group and Protein Metrics Inc. today have launched a strategic partnership scheme to further advance glycoproteomics and biotherapeutics ...
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that it has signed a multi-year research collaboration and option agreement with ReCode Therapeutics. Under this agreement, the companies will work together to potentially discover precision genetic medicines through the development of a novel platform for full gene ...
ByBayer AG
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. Bill Athenson, CEO of Third Pole, stated, “We are thrilled to receive this investment, which raises Third Pole Therapeutics’ series B financing and commitments to date to over $85M. I am ...
PhysioAssist and the French CF patient association ‘Vaincre La Mucoviscidose’ have just signed a partnership to facilitate access to the use of the Simeox device at home. We are delighted about this partnership with the association Vaincre La Mucoviscidose, for allowing an easy access without engagement, as well as financial assistance by the association to the patients who wish to ...
We are happy to announce that the #simeox device is now commercially available in Canada. Proud to partner with Novus Medical to help respiratory clinicians improve the life of their patients through access to Simeox. The Simeox device is an efficient and comfortable therapy for distal mucus clearance – for patients suffering from chronic lung conditions associated with chest congestion, ...
Microbion Corporation today announced that the company presented a poster highlighting the effect of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC. The objectives of these studies were to further understand the mechanism of action of pravibismane, in both planktonic and ...
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued to Microbion, United States Patent No. 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane. The patent, titled “Bismuth-thiol compositions and methods for treating wounds,” adds to Microbion’s growing portfolio of intellectual property on the ...
Microbion Corporation of Bozeman, MT, today announced that it has received non-dilutive funding through its strategic partnership with CUBRC, Inc., a Buffalo-based, independent not-for-profit research company, of up to $2.1 million from the US Navy through the Medical Technology Enterprise Consortium (MTEC) partnership. The funding project is titled “Pravibismane Suspension as a Topical, ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy, have been accepted for presentation during the American Diabetes Association 82nd Annual Scientific ...
Reducing headcount by 50% to further extend capital resources Cash runway extended to at least mid-2024 Cystic Fibrosis Program remains on track with initial readout from Phase 1b/2a study of BX004 expected in the third quarter of 2022 and readout from part 2 of the study expected in the first quarter of 2023 Atopic Dermatitis Program will be delayed due to restructuring BiomX Inc. (NYSE ...
ByBiomX
The Secure Anonymised Information Linkage (SAIL) Databank holds a wealth of anonymised data collected from people in Wales over the past 30 years. This data comes from health and social care, care homes, registers and audits, specialist services and surveys, which can be anonymously linked to provide a clear picture of the health and social care setting in Wales. SAIL data has been used widely ...
BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the publication of a scientific paper titled “Exodus: Sequencing-based Pipeline for Quantification of Pooled Variants” in the journal, Bioinformatics. ...
ByBiomX
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyay has been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the pharmaceutical and medical technology sectors, serving in financial and strategy roles covering multiple areas of the life ...
Vertex grant to JDRF supports efforts to improve clinical trial diversity in type 1 diabetes The Vertex Foundation grant supports the Mass General Comprehensive Sickle Cell Disease Treatment Center Additional Vertex Foundation grant to Year Up to support health care workforce training Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex and the Vertex Foundation, ...
New 344,000 square foot cell and genetic therapies research and manufacturing facility to be built Facility to support continued R&D growth At a dedication today of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced plans to build another 344,000 square foot facility in the Seaport to ...
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)-- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, May 11, 2022, at 8:00 ...
ByBiomX
Clinical proof-of-concept achieved based on positive data from the first two patients dosed at half the target dose of cells in Part A of Phase 1/2 study First patient achieved insulin independence at Day 270; positive data in second patient; third patient has received full target dose with initiation of Part B VX-880 generally well tolerated in all three patients dosed to date ...
Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA®- Vertex has submitted this indication to CADTH & INESSS for Health Technology Assessments- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include ...